



Synthesis and biological evaluation of pyrimidine nucleoside monophosphate prodrugs targeted against influenza virus

Silvia Meneghesso^{a,1}, Evelien Vanderlinden^{b,1}, Annelies Stevaert^b, Christopher McGuigan^{a,*}, Jan Balzarini^b, Lieve Naesens^b

^aWelsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, UK

^bRega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium

ARTICLE INFO

Article history:

Received 11 October 2011

Revised 24 December 2011

Accepted 18 January 2012

Available online 28 January 2012

Keywords:

Uridine-based nucleoside analogues

ProTide

RNA polymerase

Carboxypeptidase Y

ABSTRACT

Uridine-based nucleoside analogues have often been found to have relatively poor antiviral activity. Enzymatic assays, evaluating inhibition of influenza virus RNA polymerase, revealed that some uridine triphosphate derivatives displayed inhibitory activity on UTP incorporation into viral RNA. Here we report the synthesis, antiviral activity and enzymatic evaluation of novel ProTides designed to deliver the activated (monophosphorylated) uridine analogues inside the influenza virus-infected cells. After evaluation of the activation profile we identified two ProTides with moderate antiviral activity in MDCK cells (**23a**, $EC_{99} = 49 \pm 38 \mu\text{M}$ and **23b**, $EC_{99} \geq 81 \mu\text{M}$) while the corresponding nucleoside analogue (2'-fluoro-2'-deoxyuridine) was inactive. Thus, at least in these cases the poor antiviral activity of the uridine analogues may be ascribed to poor phosphorylation.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Most antiviral nucleoside compounds inhibit viral genome replication by acting as mimetics of the natural nucleosides. Nucleoside analogues (NAs) can either act as chain terminators after being incorporated into growing DNA/RNA strands and/or inhibit the viral polymerase function by competition with the natural nucleoside 5'-triphosphate substrate (Wagner et al., 2000). Since most NAs exert their antiviral activities as their 5'-triphosphate form, phosphorylation is critical to activate these compounds. In most cases, the first step of phosphorylation represents the rate-limiting step of the bioactivation and its inefficiency may limit the therapeutic potential of the NA (Jones and Bischofberger, 1995). Bypassing this rate-limiting activation step may improve or extend the biological activity of the NAs and may be a good strategy to broaden their spectrum of activity. However, nucleoside 5'-monophosphates cannot be delivered directly into cells because of their instability in biological media and poor diffusion through cell membranes due to their negative charges. One approach to overcome these issues is to mask the negative charges of the monophosphate moiety with lipophilic substituents. A variety of monophosphate prodrug approaches have been developed based upon intracellular cleavage of the masking group to release the monophosphate inside the cell (Jones and Bischofberger, 1995; Meier, 1998; Hecker and Erion, 2008). The aryloxy phosphoramidate

approach, known as the ProTide concept, has emerged as a versatile method to obtain intracellular levels of nucleoside 5'-monophosphates and several studies have yielded a detailed insight into their intracellular activation pathway (Mehellou et al., 2009).

Most antiviral pyrimidine analogues reported in the literature act as mimetics of either thymidine or cytidine (Field and De Clercq, 2008; De Clercq and Field, 2008). Uridine-based nucleoside analogues have often been found to have relatively poor antiviral activity, which may be related to the inefficient phosphorylation of uridine-based compounds.

In the study reported here, enzymatic assays with influenza virus polymerase revealed that some uridine 5'-triphosphate (UTP) derivatives display inhibitory activity to incorporation of UTP into influenza virus RNA. In particular, 5-bromouridine 5'-triphosphate and 2'-deoxy-2'-fluorouridine 5'-triphosphate demonstrated 50% inhibitory concentrations below $10 \mu\text{M}$. Based on these intriguing enzymatic inhibition data, we applied the phosphoramidate approach to a selection of modified uridines, with the purpose to deliver the nucleoside 5'-monophosphate inside the cell thereby potentially increasing the activity of the nucleoside analogues against influenza virus. Notably, in each case the parent NA was devoid of anti-influenza activity.

2. Materials and methods

2.1. Experimental chemistry

All anhydrous solvents were bought from Aldrich and all reagents commercially available were used without further

* Corresponding author. Tel./fax: +44 2920874537.

E-mail address: mcguigan@cardiff.ac.uk (C. McGuigan).

¹ These authors contributed equally to this work.

purification. Thin Layer Chromatography (TLC): precoated, aluminum backed plates (60 F₂₅₄, 0.2 mm thickness, Merck) were visualized under both short and long wave ultraviolet light (254 nm and 366 nm). Preparative TLC plates (20 × 20 cm, 500–2000 µm) were purchased from Merck. Column chromatography processes were carried out using silica gel supplied by Fisher (35–70 µm). Glass columns were slurry packed using the appropriate eluent and samples were applied either as a concentrated solution in the same eluent or pre-adsorbed on silica gel. Analytical and semi-preparative HPLC were conducted using a Varian Prostar system while the software used was Galaxie Chromatography Data System. Only compounds with purity ≥95% were considered in this study. Nuclear Magnetic Resonance (NMR): ¹H NMR (500 MHz), ¹³C NMR (125 MHz), ³¹P NMR (202 MHz) and ¹⁹F NMR (470 MHz) were recorded on a Bruker Avance 500 MHz spectrometer at 25 °C. Spectra were calibrated to the residual signal of the deuterated solvent used. Chemical shifts are given in parts per million (ppm) and coupling constants (*J*) in Hertz. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), m (multiplet), bs (broad singlet), dd (doublet of doublet). Mass Spectroscopy (MS): high resolution mass spectroscopy was performed at the School of Chemistry, Cardiff University, using electrospray (ES).

2.1.1. Standard procedure A: synthesis of phosphorochloridates **4a–b**, **6a–b**

Anhydrous triethylamine (2.00 mol equiv) was added dropwise at –78 °C to a stirred solution of the appropriate phosphorodichloridate (1.00 mol equiv) and the appropriate amino acid ester salt (1.00 mol equiv) in anhydrous DCM (30–40 mL) under an argon atmosphere. After 1 h the reaction was allowed to slowly warm to room temperature and stirred for 2–3 h. The formation of the desired compound was monitored by ³¹P NMR. The solvent was removed under reduced pressure and the crude residue purified by flash column chromatography (ethyl acetate/hexane 1/1) to give the product as oil.

2.1.1.1. Synthesis of 1-naphthyl-(benzoxy-L-alaninyl)-phosphorochloridate 4a. Prepared according to Standard procedure A, using **2** (1.86 g, 7.11 mmol), **3a** (2.50 g, 7.11 mmol), anhydrous triethylamine (1.98 mL, 14.22 mmol) in anhydrous DCM (40 mL). The reaction mixture was stirred at –78 °C for 1 h, then at room temperature for 2 h to give the product as a pale yellow oil (75%, 2.16 g). ³¹P NMR (CDCl₃, 202 MHz): δ 8.23, 8.02. ¹H NMR (CDCl₃, 500 MHz): δ 8.10–7.30 (12H, m, NaphO, OCH₂Ph), 5.21, 5.19 (2H, m, OCH₂Ph), 4.70–4.64 (1H, m, NH), 4.42–4.33 (1H, m, CHCH₃), 1.59–1.57 (3H, 2d, *J* = 7.0 Hz, CH₃).

2.1.1.2. Synthesis of phenyl-(benzoxy-L-alaninyl)-phosphorochloridate 6a. Prepared according to Standard procedure A, using **5** (1.06 mL, 7.11 mmol) **3a** (2.50 g, 7.11 mmol), anhydrous triethylamine (1.98 mL, 14.22 mmol) in anhydrous DCM (40 mL). The reaction mixture was stirred at –78 °C for 1 h, then at room temperature for 2 h to give the product as a pale yellow oil (90%, 2.27 g). ³¹P NMR (CDCl₃, 202 MHz): δ 7.90, 7.58. ¹H NMR (CDCl₃, 500 MHz): δ 7.44–7.25 (10H, m, PhO, OCH₂Ph), 5.24, 5.23 (2H, m, OCH₂Ph), 4.40 (1H, bs, NH), 4.34–4.21 (1H, m, CHCH₃), 1.54, 1.53 (3H, 2d, *J* = 7.0 Hz, CH₃).

2.1.2. Standard procedure B: synthesis of 2',3'-O-protected nucleosides **15**, **16**

To a solution of the appropriate nucleoside in anhydrous cyclopentanone, HClO₄ (3.00–4.00 mol equiv) was added and the reaction mixture was stirred at room temperature for 5 h. The reaction was then neutralized with a saturated solution of NaHCO₃. The solvent was removed under reduced pressure and the crude

residue purified by flash column chromatography (gradient elution of DCM/MeOH = 98/2 then 96/4).

2.1.3. Standard procedure C: synthesis of phosphoramidates **17a–c**, **18a–c**, **21a–c**, **22a**, **23a–c**

BuMgCl (1.0 M solution in THF, 1.10 to 2.00 mol equiv) was added to a suspension/solution of the appropriate nucleoside (1.00 mol equiv) in anhydrous THF (10 mL) under an argon atmosphere and stirred at room temperature for 30 min. The appropriate phosphorochloridate (2.00 mol equiv) dissolved in anhydrous THF was added dropwise and the reaction mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure and the crude residue purified by flash column chromatography (gradient elution of DCM/MeOH) to give the desired product.

2.1.3.1. Synthesis of 2',3'-O,O-cyclopentylidene-5-iodouridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 17a. Prepared according to Standard Procedure C, using **15** (0.20 g, 0.46 mmol) in anhydrous THF (10 mL), ^tBuMgCl (1.0 M solution in THF, 0.92 mL, 0.92 mmol) and **4a** (0.37 g, 0.92 mmol) and the reaction mixture was stirred at room temperature overnight. The crude was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white solid (81%, 0.30 g). ³¹P NMR (MeOD, 202 MHz): δ 4.00, 3.77. ¹H NMR (MeOD, 500 MHz): δ 8.26–7.13 (13H, m, Naph, OCH₂Ph, H-6), 5.92–5.80 (1H, m, H-1'), 5.14–5.01 (2H, m, OCH₂Ph), 4.78–4.66 (1H, m, H-3'), 4.66–4.52 (1H, m, H-2'), 4.42–4.25 (3H, m, H-4', H-5'), 4.21–4.06 (1H, m, CHCH₃), 2.06–1.51 (8H, m, CH₂-cyclopentyl), 1.45–1.26 (3H, m, CHCH₃).

2.1.3.2. Synthesis of 2',3'-O,O-cyclopentylidene-5-bromouridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 18a. Prepared according to Standard Procedure C, using **16** (0.20 g, 0.51 mmol) in anhydrous THF (10 mL), ^tBuMgCl (1.0 M solution in THF, 1.00 mL, 1.00 mmol) and **4a** (0.42 g, 1.03 mmol) and the reaction mixture was stirred at room temperature overnight. The crude was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white solid (63%, 0.24 g). ³¹P NMR (MeOD, 202 MHz): δ 4.07, 3.84. ¹H NMR (MeOD, 500 MHz): δ 8.19–7.25 (13H, m, NaphO, OCH₂Ph, H-6), 5.70–5.69 (1H, m, H-1'), 5.13–5.07 (2H, m, OCH₂Ph), 4.62–4.64 (1H, m, H-2'), 4.51–4.53 (1H, m, H-3'), 4.41–4.26 (3H, m, H-4', H-5'), 4.18–4.04 (1H, m, CHCH₃), 2.04–1.83 (2H, m, CH₂-cyclopentyl), 1.80–1.58 (6H, m, CH₂-cyclopentyl), 1.43–1.31 (3H, m, CHCH₃).

2.1.3.3. Synthesis of 5-methyl-uridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 21a. Prepared according to Standard Procedure C, using **12** (0.30 g, 1.16 mmol) in anhydrous THF (10 mL), ^tBuMgCl (1.0 M solution in THF, 1.40 mL, 1.40 mmol) and **4a** (0.94 g, 2.32 mmol) and the reaction mixture was stirred at room temperature overnight. Then ^tBuMgCl (1.0 M solution in THF, 1.40 mL, 1.40 mmol) was added, and after 3 h the solution was concentrated. The crude was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4). The product was further purified by preparative TLC (gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white solid (3%, 0.02 g). ³¹P NMR (MeOD, 202 MHz): δ 4.12, 4.09. ¹H NMR (MeOD, 500 MHz): δ 8.27, 7.31 (12H, m, NaphO, OCH₂Ph), 7.48 (1H, m, H-6), 5.93–5.90 (1H, m, H-1'), 5.13–5.05 (2H, m, OCH₂Ph), 4.47–4.29 (2H, m, H-3', H-4'), 4.23–4.11 (3H, m, H-2', H-5'), 4.10–4.04 (1H, m, CHCH₃), 1.67–1.65 (3H, m, CH₃), 1.34–1.33 (3H, m, CHCH₃). ¹³C NMR (MeOD, 126 MHz): δ 12.34, 12.42 (CH₃-Uridine), 20.27 (d, *J*_{C-P} = 7.5 Hz, CH₃-Ala), 20.39 (d, *J*_{C-P} = 6.6 Hz, CH₃-Ala), 51.80, 51.88 (CH-Ala), 67.57 (d, *J*_{C-P} = 5.7 Hz, C-5'), 67.69 (d, *J*_{C-P} = 5.2 Hz, C-5'), 68.03 (OCH₂Ph), 71.13 (C-2'), 74.89, 74.94 (C-3'), 83.83, 83.88, 83.85, 83.89, 83.93 (C-4'), 90.50, 90.62 (C-1'), 111.98 (C-5),

116.15, 116.18, 116.21, 122.58, 122.74, 126.08, 126.11, 126.41, 126.49, 126.52, 127.08, 127.46, 127.57, 127.86, 127.88, 128.52, 128.91, 128.96, 129.13, 129.31, 129.34, 129.36, 129.46, 129.59 (C-6, C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, OCH₂Ph), 136.33, 137.14, 137.29 (C-4a Naph, "ipso" OCH₂C-Ph), 147.82, 147.88 ("ipso" C-Naph, C-2), 147.95, 147.92 (C-4), 174.53, 174.57, 174.83, 174.85 (COOCH₂Ph). HRMS = (C₃₀H₃₃N₃O₁₀P) calculated 626.1905, found 625.1907. HPLC = H₂O/MeOH from 90/100 to 0/100 in 30 min = retention time 25.61, 25.88 min.

2.1.3.4. Synthesis of 5-bromo-2'-deoxyuridine-5'-O-phenyl-(benzoxy-L-alaninyl)-phosphate 22a. Prepared according to *Standard Procedure C*, using **13** (0.20 g, 0.65 mmol) in anhydrous THF (10 mL), ^tBuMgCl (1.0 M solution in THF, 0.78 mL, 0.78 mmol) and **6a** (0.46 g, 1.30 mmol) and the reaction mixture was stirred at room temperature overnight. Then ^tBuMgCl (1.0 M solution in THF, 0.78 mL, 0.78 mmol) was added, and after 2 h the solution was concentrated. The crude was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white solid (23%, 0.10 g). ³¹P NMR (MeOD, 202 MHz): δ 4.06, 3.60. ¹H NMR (MeOD, 500 MHz): δ 7.99, 7.98 (1H, 2s, H-6), 7.40–7.17 (10H, m, PhO, OCH₂Ph), 6.23–6.16 (1H, m, H-1'), 5.15–5.14 (2H, m, OCH₂Ph), 4.40–4.36 (1H, m, H-3'), 4.33–4.23 (2H, m, H-5'), 4.10–4.07 (1H, m, CHCH₃), 4.06–3.96 (1H, m, H-4'), 2.37–1.85 (2H, m, H-2'), 1.38–1.36 (3H, m, CHCH₃). ¹³C NMR (MeOD, 126 MHz): δ 19.56 (d, J_{C-P} = 7.1 Hz, CH₃-Ala), 29.54 (d, J_{C-P} = 6.4 Hz, CH₃-Ala), 41.03, 41.38 (C-2'), 50.82, 50.96 (CH-Ala), 66.83, 66.96 (2d, J_{C-P} = 5.5 Hz, C-5'), 67.22 (OCH₂Ph), 71.22, 71.37 (C-3'), 86.49, 86.57 (C-4'), 96.64 (C-5), 105.34 (C-1'), 120.60, 120.63, 120.64, 120.66, 125.41, 125.48, 128.50, 128.56, 128.58, 128.64, 128.78, 128.84, 129.97, 129.99 (2 Ph), 136.29, 136.36 ('ipso' OCH₂C-Ph), 140.40, 140.46 (C-6), 150.49, 150.53, 150.60 ('ipso', C-Ph), 151.19, 151.24, 151.29 (C-2), 160.64, 160.72 (C-4), 173.71 (d, J_{C-P} = 4.9 Hz, COOCH₂Ph), 173.97 (d, J_{C-P} = 4.4 Hz, COOCH₂Ph). HRMS = (C₂₅H₂₈N₃O₉PBr) calculated 624.0747, found 624.0753. HPLC = H₂O/MeOH from 90/100 to 0/100 in 30 min = retention time 24.28, 24.49 min.

2.1.3.5. Synthesis of 2'-deoxy-2'-fluorouridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 23a. Prepared according to *Standard Procedure C*, using **14** (0.30 g, 1.22 mmol) in anhydrous THF (10 mL), ^tBuMgCl (1.0 M solution in THF, 1.46 mL, 1.46 mmol) and **4a** (0.98 g, 2.44 mmol) and the reaction mixture was stirred at room temperature overnight. Then **4a** (0.49 g, 1.22 mmol) and ^tBuMgCl (1.0 M solution in THF, 1.02 mL, 1.02 mmol) were added, and after 2 h the solution was concentrated. The crude was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4). The product was further purified by preparative TLC (gradient elution of DCM/MeOH = 98/2, then 96/4) to give a white solid (4%, 0.03 g). ³¹P NMR (MeOD, 202 MHz): δ 4.26, 4.08. ¹⁹F NMR (MeOD, 470 MHz): δ -203.46, -203.88. ¹H NMR (MeOD, 500 MHz): δ 8.19–7.29 (13H, m, Naph-O, OCH₂Ph, H-6), 5.92 (0.5H, dd, J_{H-H} = 1.9 Hz, J_{H-F} = 18.5 Hz, H-1' of one diastereoisomer), 5.91 (0.5H, dd, J_{H-H} = 1.9 Hz, J_{H-F} = 18.8 Hz, H-1' of one diastereoisomer), 5.43, 5.42 (1H, 2s, H-5), 5.09–5.11 (2H, m, OCH₂Ph), 4.99–4.87 (1H, m, H-2'), 4.54–4.34 (1H, m, H-5'), 4.33–4.29 (1H, m, H-3'), 4.15–4.14 (1H, m, H-4'), 4.12–4.07 (1H, m, CHCH₃), 1.37–1.29 (3H, m, CHCH₃). ¹³C NMR (MeOD, 126 MHz): δ 20.28 (d, J_{C-P} = 7.6 Hz, CH₃-Ala), 20.45 (d, J_{C-P} = 6.6 Hz, CH₃-Ala), 51.79, 51.88 (CH-Ala), 66.30 (d, J_{C-P} = 4.7 Hz, C-5'), 66.72 (d, J_{C-P} = 5.3 Hz, C-5'), 68.04 (OCH₂Ph), 69.54 (d, J_{C-P} = 16.6 Hz, C-3'), 69.73 (d, J_{C-P} = 16.6 Hz, C-3'), 83.43, 82.50 (C-4'), 90.49 (d, J_{C-F} = 35.4 Hz, C-1'), 90.67 (d, J_{C-F} = 35.4 Hz, C-1'), 94.28 (d, J_{C-F} = 187.3 Hz, C-2'), 94.30 (d, J_{C-F} = 187.3 Hz, C-2'), 103.01, 103.10 (C-5), 116.20, 116.28, 122.61, 122.72, 126.12, 126.59, 127.61, 127.90, 128.95, 128.99, 129.28, 129.33, 129.59 (C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph,

C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, OCH₂Ph), 136.34 (C-4a Naph, 'ipso' OCH₂C-Ph), 142.32, 142.34 (C-6), 147.86, 147.92 ('ipso', C-Naph, C-2), 151.84 (C-4), 174.57, 174.59 (COOCH₂Ph). HRMS = (C₂₉H₂₉N₃O₉PFNa) calculated 636.1643, found 636.1650. HPLC = H₂O/MeOH from 90/100 to 0/100 in 30 min = retention time 20.39, 21.09 min.

2.1.4. Standard procedure D: deprotection of 2',3'-sugar protected phosphoramidates **19a–c**, **20a–c**

A solution of the appropriate 2',3'-sugar protected phosphoramidate in 60% formic acid was stirred at room temperature overnight. The solvent was removed under reduced pressure and the crude residue was purified by column chromatography (gradient elution of DCM/MeOH = 98/2, then 96/4).

2.1.4.1. Synthesis of 5-iodouridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 19a. Prepared according to *Standard Procedure D*, using **17a** (0.30 g, 0.37 mmol) in 60% formic acid (30 mL) and the reaction mixture was stirred at room temperature overnight to give a white solid (22%, 0.06 g). ³¹P NMR (MeOD, 202 MHz): δ 4.21, 3.95. ¹H NMR (MeOD, 500 MHz): δ 8.32–7.20 (13H, m, Naph, OCH₂Ph, H-6), 5.86–5.81 (0.5H, m, H-1' of one diastereoisomer), 5.80 (0.5H, d, J = 3.5 Hz, H-1' of one diastereoisomer), 5.14–5.00 (2H, m, OCH₂Ph), 4.50–4.19 (3H, m, H-3', H-2', H-4'), 4.19–4.03 (3H, m, CHCH₃, H-5'), 1.42–1.26 (3H, m, CHCH₃). ¹³C NMR (MeOD, 126 MHz): δ 20.44 (d, J_{C-P} = 7.3 Hz, CH₃-Ala), 20.57 (d, J_{C-P} = 6.4 Hz, CH₃-Ala), 51.87, 51.90 (CH-Ala), 67.65 (d, J_{C-P} = 5.3 Hz, C-5'), 67.43 (d, J_{C-P} = 5.2 Hz, C-5'), 68.10, 68.11 (OCH₂Ph), 69.44, 69.47 (C-5), 70.80, 70.95 (C-2'), 74.95, 75.07 (C-3'), 84.07, 84.13, 84.19 (C-4'), 91.41 (d, J_{C-P} = 19.8 Hz, H-1'), 91.42 (d, J_{C-P} = 19.8 Hz, H-1'), 116.21, 116.24, 116.34, 116.36, 122.73, 122.93, 126.09, 126.55, 127.56, 127.84, 128.93, 129.19, 129.53, 129.60 (C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, OCH₂Ph), 136.32, 137.11 (C-4a Naph, 'ipso' OCH₂C-Ph), 146.67, 146.74 (C-6), 147.87, 147.94, 148.01 ('ipso' Naph), 152.09 (C-2), 162.60 (C-4), 174.48, 174.61, 174.78, 174.84 (COOCH₂Ph). HRMS = (C₂₉H₂₉N₃O₁₀PINa) calculated 760.0510, found 760.0515. HPLC = H₂O/MeOH from 90/100 to 0/100 in 30 min = retention time 25.75, 26.16 min.

2.1.4.2. Synthesis of 5-bromouridine-5'-O-naphthyl-(benzoxy-L-alaninyl)-phosphate 20a. Prepared according to *Standard Procedure D*, using **18a** (0.24 g, 0.32 mmol) in 60% formic acid (30 mL) to give a white solid (25%, 0.05 g). ³¹P NMR (MeOD, 202 MHz): δ 4.23, 4.01. ¹H NMR (MeOD, 500 MHz): δ 8.23–7.20 (13H, m, NaphO, OCH₂Ph, H-6), 5.86 (0.5H, d, J = 1.7 Hz, H-1' of one diastereoisomer), 5.85 (0.5H, d, J = 1.6 Hz, H-1' of one diastereoisomer), 5.11–4.99 (2H, m, OCH₂Ph), 4.48–4.30 (3H, m, H-4', H-5'), 4.20–4.06 (3H, m, H-2', H-3', CHCH₃), 1.43–1.32 (3H, m, CHCH₃).

¹³C NMR (MeOD, 126 MHz): δ 20.40 (d, J_{C-P} = 7.3 Hz, CH₃-Ala), 20.51 (d, J_{C-P} = 6.6 Hz, CH₃-Ala), 51.84, 51.89 (CH-Ala), 67.36 (d, J_{C-P} = 4.9 Hz, C-5'), 67.57 (d, J_{C-P} = 5.3 Hz, C-5'), 68.09 (OCH₂Ph), 70.90, 70.96 (C-2'), 75.06, 75.19 (C-3'), 84.05, 84.11, 84.18 (C-4'), 91.32, 91.50 (H-1'), 97.81 (C-5), 116.20, 116.23, 116.26, 116.29, 122.67, 122.85, 126.10, 126.51, 127.50, 127.55, 127.83, 127.85, 128.91, 128.94, 129.31, 129.34, 129.38, 129.59 (C-2 Naph, C-3 Naph, C-4 Naph, C-5 Naph, C-6 Naph, C-7 Naph, C-8 Naph, C-8a Naph, OCH₂Ph), 136.32 (C-4a Naph), 137.10, 137.13 ('ipso' OCH₂C-Ph), 141.51, 141.63 (C-6), 147.89, 147.95 ('ipso' C-Naph), 151.68 (C-2), 161.39 (C-4), 174.60 (d, J_{C-P} = 4.6 Hz, COOCH₂Ph), 174.80 (d, J_{C-P} = 4.3 Hz, COOCH₂Ph). HRMS = (C₂₉H₂₉N₃O₁₀PBrNa) calculated 712.0672, found 712.0694. HPLC = H₂O/MeOH from 90/100 to 0/100 in 30 min = retention time 25.59, 26.01 min.

2.2. Biological experiments

2.2.1. Purification of viral ribonucleoprotein complexes

The procedure for purification of viral vRNP complexes from disrupted influenza virions was developed many years ago (Plotch et al., 1981; Rochovansky, 1976). Influenza A/X-31 [A/Aichi/2/68 (H3N2) × A/PR/8/34 (H1N1)] virus was inoculated in 10-day-old embryonated chicken eggs and incubated for 48 h at 37 °C. After clarification of the allantoic fluid (total volume: 150 ml) by centrifugation (1800g; 30 min; 4 °C), the virus was pelleted by ultracentrifugation (35,000g; 3 h; 4 °C) in a sucrose/NTE buffer, consisting of 30% sucrose, 0.1 M NaCl, 0.01 M Tris HCl, 0.001 M EDTA at pH 7.4. The virus pellet was disrupted by incubation at 31 °C for 25 min in a buffer containing 0.1 M Tris, pH 8.1, 0.1 M KCl, 5 mM MgCl₂, 5% glycerol, 1.5% triton-N 101, 10 mg/ml lysolecithin and 1.5 mM dithiothreitol (DTT). Then, the viral lysate was subjected to ultracentrifugation (288,000g; 6 h; 4 °C) on a discontinuous (33–40–50–70%) glycerol gradient in a buffer with 0.15 M NaCl and 48.5 mM Tris, pH 7.8. The polymerase-containing fractions were identified by Western blot, using an anti-PB2 antibody (Tebu-Bio) and a horseradish peroxidase-labeled secondary antibody. Pooled fractions were dialyzed overnight at 4 °C against storage buffer (50 mM Tris, pH 7.6, 100 mM NaCl, 10 mM MgCl₂, 2 mM DTT and 50% (V/V) glycerol) with a Slide-A-Lyzer Dialysis Cassette MW 10,000 (Pierce), and stored at –80 °C.

2.2.2. Enzymatic assay with influenza virus polymerase

The modified UTP analogues were purchased from TriLink Bio-technologies, whereas [5-³H]-UTP (specific activity: 23.1 Ci/mmol) was from Moravsek. The influenza virus vRNP (2 µL) was incubated for 60 min at 30 °C in a reaction mixture (final volume: 25 µL) consisting of 50 mM Tris, pH 8.0, 100 mM KCl, 1 mM DTT, 5 mM MgCl₂, 0.4 U/µL Recombinant RNasin (Promega), 200 µM ApG primer [adenyl (3'–5') guanosine, obtained from Sigma], 100 µM GTP, 100 µM CTP, 500 µM ATP, 2 µM UTP and 1.7 µM [5-³H]UTP, with or without test compounds. The enzyme reaction was terminated by the addition of 1.0 mL of a mixture containing 10% trichloroacetic acid (TCA) and 20 mM Na₂P₂O₄. After 30 min incubation on ice, precipitates were spotted onto glass microfibre filters and washed 10 times with 5% TCA, and once with denaturated ethanol. Then, the filters were dried during 2 h and incorporated radioactivity was determined by liquid scintillation counting. The IC₅₀ was calculated by extrapolation, and defined as the compound concentration showing 50% reduction in incorporated radioactivity, as compared to the condition receiving no inhibitor.

2.2.3. Antiviral assay in influenza virus-infected MDCK cells

Details on virus strain, cells and media can be found elsewhere (Vanderlinden et al., 2010). One day prior to infection, Madin Darby canine kidney (MDCK) cells were seeded in 96-well plates at 25 000 cells per well. Cells were infected with influenza A virus (strain A/X-31) at a multiplicity of infection of 0.0004 plaque-forming units per cell. After adding serial dilutions of the test compounds, the plates were incubated during 24 h at 35 °C, when supernatants were collected and stored at –80 °C. An aliquot (4 µL) was mixed with 22 µL lysis reagent to disrupt the virus particles, following the instructions inserted in the Cellsdirect One-step qRT-PCR kit from Invitrogen. After 10 min heating at 75 °C, 10 µL lysate was transferred to a qPCR plate containing the RT-PCR enzymes and buffer, and influenza virus M1-specific primers and probe (as described in Vanderlinden et al., 2010). The RT-PCR program consisted of: 15 min at 50 °C; 2 min at 95 °C; and 40 cycles of 15 s at 95 °C followed by 90 s at 60 °C. Absolute quantitation of vRNA copies was performed by including an M1-plasmid standard. The EC₉₉ was calculated by extrapolation and defined as the compound concentration causing a 2-log₁₀ reduction in the amount of vRNA

copies, as compared to untreated virus control. In parallel, compound cytotoxicity was estimated from the morphological changes in MDCK cells observed by microscopy after three days incubation with the test compounds.

2.2.4. Enzymatic assays using carboxypeptidase Y and cell lysate

The carboxypeptidase Y experiment was performed using ³¹P NMR and recording 1 experiment every 7 min within 14 h. The ProTides were dissolved in d₆-acetone and Trizma buffer (pH 7.6) and a solution of carboxypeptidase Y in Trizma buffer was added after recording the blank for each sample (Derudas et al., 2009).

The cell lysate experiment was performed using a concentrated cell lysate prepared from 10⁷ HuH7 hepatocyte cells, which was incubated with the ProTides in deuterium oxide and dimethylsulfoxide at 37 °C. ³¹P NMR spectra were recorded every 30 min within 14 h.

2.2.5. Metabolism in MDCK cells

MDCK cells were seeded at 1500,000 cells per 25 cm² flask and incubated at 35 °C for 24 h. 5-Bromouridine (**11**) or its Protide **20a** were added to a final concentration of 250 µM, and the cells were further incubated at 37 °C for 24 or 48 h. To prepare the HPLC extracts, the cells were rinsed twice with DMEM and detached by trypsinization at 37 °C for 10 min. After collection of the cell pellet by centrifugation (290g, 10 min, 4 °C), extraction was performed with 200 µL ice-cold methanol 66%. After 10 min incubation on ice, followed by centrifugation (15,700g, 10 min, 4 °C), the clarified extracts were subjected to HPLC analysis. Therefore, 100 µL extract was injected onto an anion-exchange Partisphere SAX column (dimensions: 4.6 mm × 125 mm) from Whatman (Maidstone, UK), and separated with two phosphate buffers (A: 5 mM and B: 0.3 M ammonium dihydrogen phosphate; both at pH 5), and the following gradient (flow: 2 ml per min): 100% A (5 min); linear gradient to 100% B (15 min); 100% B (20 min); linear gradient to 100% A (5 min) and 100% A (5 min). UV absorbance was measured with a photodiode-array detector, allowing simultaneous detection at 260 nm (λ_{max} for UTP) and 280 nm (λ_{max} for 5-Br-UTP).


3. Results and discussion

3.1. Chemistry


The synthesis of the first synthon, the requisite phosphorochloridate, involves the phosphorylation of the aromatic alcohol and subsequent coupling with the appropriate amino acid ester salts to give the desired compounds **4a–b** and **6a–b** (Scheme 1).

All the nucleosides were purchased, with the exception of 5-iodouridine **10**, which was synthesized in a three-step synthesis starting from uridine **7**. The first step involved the acetylation of the 2', 3' and 5' positions using dimethylaminopyridine (DMAP), anhydrous triethylamine (TEA) and acetic anhydride in acetonitrile to yield **8**. Selective iodination took place using iodine and cerium (IV) ammonium nitrate (CAN) in acetonitrile under anhydrous conditions to obtain compound **9** in 98% yield (Asakura and Robins, 1990). Finally, the deprotection step was carried out with sodium methoxide and methanol to yield compound **10** (Scheme 2).


Compounds **10** and **11** were protected on the sugar level (2'–3' positions), before performing the coupling reaction with the appropriate phosphorochloridate, using an excess of cyclopentanone, while the deprotection of the blocked ProTide was carried out using 60% formic acid in water. The coupling reactions between the phosphorochloridates (**4a–b** and **6a–b**) and the unprotected and protected nucleosides (**12–16**) were carried out in anhydrous tetrahydrofuran, using 1.1–2 equivalents of ^tBuMgCl as a base (Schemes 3 and 4) (Uchiyama et al., 1993).



Scheme 1. Reagents and conditions: (i) phosphorus oxychloride, dry triethylamine, dry diethyl ether, -78°C , 1 h, then rt overnight (ii) anhydrous triethylamine, anhydrous DCM, -78°C , 1 h, then rt 2 h.



Scheme 2. Reagents and conditions: (i) acetic anhydride, anhydrous triethylamine, DMAP, anhydrous CH_3CN , rt, 1 h; (ii) I_2 , CAN, CH_3CN , 80°C , 1 h; (iii) NaOMe, anhydrous MeOH, rt, 2 h.




Scheme 3. Reagents and conditions: (i) cyclopentanone, HClO_4 , rt, overnight, (ii) $t\text{BuMgCl}$, anhydrous THF, appropriate phosphorochloridate, rt, overnight; (iii) 60% formic acid, rt, overnight.

Based on our previous insights in the ProTide structure–activity relationships (Cahard et al., 2004), we chose to synthesize ProTides with either phenyl or 1-naphthyl as the aromatic moiety. L-Alanine was the preferred amino acid substituent while benzyl and methyl were chosen as the amino acid ester substituents. In this way, our SAR study was mainly focused on how base- or sugar-modifications in the uridine part of these ProTides would impact their bioactivation and antiviral activity against influenza virus. All compounds were characterized and isolated as equimolar mixtures of phosphorus diastereoisomers as judged by ^{31}P NMR, and each displayed purity above 95% as determined by analytical HPLC.

3.2. RNA polymerase assays

Various base- or sugar-modified UTP derivatives were selected for inhibition studies in an enzymatic assay with influenza virus polymerase (Table 1). The assay is based on incorporation of radiolabeled UTP into viral cRNA upon ApG-primed RNA synthesis by purified influenza virus ribonucleoprotein (vRNP) complexes, which contain the heterotrimeric influenza virus polymerase and the viral RNA template bound to nucleoprotein (Vreede and Brownlee, 2007). Under our experimental conditions, the obligate chain terminator 3'-deoxy-UTP yielded an IC_{50} value of $68\ \mu\text{M}$, as



Scheme 4. Reagents and conditions: (i) $t\text{BuMgCl}$, anhydrous THF, appropriate phosphorochloridate, rt, overnight.

Table 1
Inhibitory effect of base- or sugar-modified UTP analogues on RNA incorporation of radiolabeled UTP by INF vRNP.

Compound	IC_{50} (μM) ^a
<i>Base-modified analogues</i>	
2-Thio-UTP	>400
4-Thio-UTP	45 ± 8
6-Aza-UTP	>400
5-Fluoro-UTP	36 ± 4
5-Bromo-UTP	7.1 ± 0.4
5-Iodo-UTP	20 ± 1
5,6-Dihydro-UTP	389
5-Methyl-UTP	20 ± 4
<i>Sugar-modified analogues</i>	
3'-Deoxy-UTP	68 ± 9
3'-O-Methyl-UTP	>400
3'-Azido-2',3'-dideoxy-UTP	>400
2'-O-Methyl-UTP	345
2'-Fluoro-2'-deoxy-UTP	14 ± 3
2'-Azido-2'-deoxy-UTP	220
2'-Amino-2'-deoxy-UTP	205
2'-Ara-UTP	72 ± 49
<i>Base- and sugar-modified analogues</i>	
2'-Deoxy-5-bromo-UTP	>400
3'-Deoxy-5-methyl-UTP	>400
2'-O-Methylpseudo-UTP	>400
2'-O-Methyl-5-methyl-UTP	>400
2'-Fluoro-2'-deoxy-5-methyl-UTP	9.5 ± 1.8

^a Compound concentration causing 50% inhibition of $[5\text{-}^3\text{H}]\text{-UTP}$ incorporation during INF vRNP-mediated RNA synthesis. Values are the mean $\pm$ SEM of two to four independent experiments.

shown in the table. Compared to this reference compound, several UTP derivatives were considerably more active, the two most potent inhibitors being 5-bromo-UTP (IC_{50} : $7.1\ \mu\text{M}$) and 2'-fluoro-2'-deoxy-5-methyl-UTP (IC_{50} : $9.5\ \mu\text{M}$). Intermediate inhibitory activity was noted for 5-methyl-UTP, 5-iodo-UTP and 2'-fluoro-2'-deoxy-UTP (IC_{50} : 20, 20 and $14\ \mu\text{M}$, respectively), whereas weak inhibitory activity was obtained with 5-fluoro-UTP, 4-thio-UTP and 2'-ara-UTP (IC_{50} : 36, 45 and $68\ \mu\text{M}$, respectively). The inhibitory effect of 5-bromo-UTP, 5-iodo-UTP and 5-methyl-UTP on the incorporation of radiolabeled UTP by the influenza virus polymerase could indicate that these modified nucleotides may act as alternative substrates for the natural UTP substrate. Likewise, many eukaryotic or prokaryotic polymerases are known to be relatively tolerant to pyrimidine modifications at the 5 position (Hoczek and Fojta, 2008). This explains the common use of 5-bromo-2'-deoxy-uridine and 5-bromouridine (or liposomal forms of their 5'-triphosphates), for intracellular labeling of nascent cellular or viral nucleic acids (Vecchio et al., 2008). Many years ago, Nakayama and Saneyoshi (1984) studied whether base-substituted UTP analogues can serve as alternative substrates for UTP incorporation

Table 2
Inhibitory effect of base- or sugar-modified UMP ProTides on influenza virus replication in MDCK cells.

Compound	Nucleoside	Aryl	Amino acid	Ester	Antiviral activity (EC ₉₉) μM^a	Cytotoxicity (MCC) μM^b
19a	5-IU	Naph	L-Ala	Bn	>100	>100
19b	5-IU	Phe	L-Ala	Bn	>100	>100
19c	5-IU	Naph	L-Ala	Me	>100	>100
20a	5-BrU	Naph	L-Ala	Bn	>100	>100
20b	5-BrU	Phe	L-Ala	Bn	>100	>100
20c	5-BrU	Naph	L-Ala	Me	>100	>100
11	5-BrU				>100	>100
21a	5-MeU	Naph	L-Ala	Bn	>100	>100
21b	5-MeU	Phe	L-Ala	Bn	>100	>100
21c	5-MeU	Phe	L-Ala	Me	>100	>100
12	5-MeU				>100	>100
22a	5-Br-2'dU	Phe	L-Ala	Bn	>100	>100
13	5-Br-2'dU				>100	>100
23a	2'F2'dU	Naph	L-Ala	Bn	49 $\pm$ 38	>100
23b	2'F2'dU	Phe	L-Ala	Bn	$\geq$ 81	>100
23c	2'F2'dU	Naph	L-Ala	Me	>100	>100
14	2'F2'dU				>100	66
Ribavirin					8.0 $\pm$ 0.8	100

^a The EC₉₉ represents the compound concentration producing a 2-log₁₀ reduction in the number of virus particles released from MDCK cells at 24 h p.i. Values are the mean $\pm$ SEM of two independent experiments.

^b Minimum cytotoxic concentration, or compound concentration causing alterations in MDCK cell morphology after three days incubation.

by cellular RNA polymerase I and II. Incorporation of 5-methyl-UTP was at least as efficient as that of UTP. Incorporation of 5-Br-UTP was more efficient than that of UTP for RNA polymerase I, and slightly less efficient for RNA polymerase II. Both 2-thio-UTP and 4-thio-UTP were less efficiently used than UTP by both RNA polymerase I and II. Our ongoing biochemical studies should reveal which of these base substitutions are indeed tolerated by the influenza virus polymerase, and whether there is a difference for the three viral RNA species [(+)mRNA, (+)cRNA or (-)vRNA] that are synthesized by this enzyme. Given that the vRNP has a highly compact structure (Resa-Infante et al., 2011), we hypothesized that a bulky 5-bromo substituent may impede the RNA elongating activity of the PB1 polymerase subunit. Unfortunately, insight into the protein structure of the catalytic site of PB1 is currently lacking. Incorporation of 5-bromo, 5-iodo or 5-methyl-UTP in nascent influenza virus RNA is expected to result in non-functional viral RNA, thus impeding its use for subsequent genome replication or synthesis of viral proteins. This provides a rationale to incorporate these base modifications when designing NAs for selective inhibition of influenza virus.

Regarding the sugar-modified analogues, we observed strong inhibition by the 2'-fluoro-2'-deoxy-derivatives of UTP and TTP. The 2'-fluoro-2'-deoxy-GTP analogue has been reported to cause nonobligate chain termination in an enzymatic influenza virus polymerase assay similar to ours (Tisdale et al., 1995). Likewise, 2'-methoxy- and 2'-C-methyl-substituted nucleotides have been extensively investigated for their inhibitory effect on the hepatitis C virus polymerase (Deval et al., 2007).

3.3. Antiviral assays

The base- or sugar-modified UMP ProTides (**19a–c**, **20a–c**, **21a–c**, **22a**, **23a–c**) were evaluated for their anti-influenza virus activity in cell culture, using a novel PCR-based virus yield assay (Table 2). With this method, the number of virus particles produced by infected MDCK cells at 24 h p.i. was quantitated by real-time RT-PCR (replacing virus titration on cells, as is done in the classical virus yield assay). The reference compound ribavirin produced a concentration-dependent reduction in virus yield. Its EC₉₉ value was 8 μM , which is very similar to the 50% antiviral effective

concentrations that we previously obtained for ribavirin in CPE reduction experiments (Vanderlinden et al., 2010). Two ProTides, **23a** and **23b**, both containing 2'-deoxy-2'-fluorouridine, were found to have weak activity against influenza virus in cell culture and their EC₉₉ values were 49 $\pm$ 38 μM and $\geq$ 81 μM , respectively. The naphthyl ProTide **23a** showed a higher activity than the phenyl analogue **23b**, and this may be due to the higher lipophilicity and therefore permeability through the cell membrane (ClogP **23a** = 2.37, ClogP **23b** = 1.20).

3.4. Metabolism study

In an attempt to explain the lack of antiviral activity of 5-bromouridine and its prodrug **20a**, a metabolic experiment was performed in MDCK cell cultures. MDCK cells were exposed to 250 μM of 5-bromouridine (**11**) or its phosphoramidate prodrug **20a** and incubated for 24 h or 48 h. Extracts of drug-exposed cells were then prepared and analyzed by anion-exchange HPLC. It was ascertained that any 5-bromo-UTP that may have sufficiently been formed intracellularly could be UV-detected at 280 nm. The standard 5-bromo-UTP (*R_t*: 20.0 min) eluted on the chromatograms between UTP (*R_t*: 19.0 min) and CTP (*R_t*: 20.5 min). Unfortunately, no formation of 5-bromo-UTP could be observed in the cell cultures exposed to either 5-bromouridine (**11**) or the protide **20a**. It should be mentioned, however, that the UV_{280nm} detection limit for non-radiolabeled 5-bromo-UTP was 440 pmol, corresponding to an intracellular 5-bromo-UTP concentration of $\sim$ 100 μM . The failure to detect measurable 5-bromo-UTP levels in cell cultures exposed to 250 μM 5-bromouridine may be not surprising given the fact that 5-bromouridine is much less efficiently phosphorylated by uridine/cytidine kinase than uridine (Van Rompay et al., 2001). Also, the 5'-mono- or 5'-diphosphate metabolites of 5-bromouridine could not be detected on the chromatograms. Moreover, limitation in the solubility of the prodrug of 5-bromouridine (**20a**) prevented us to apply higher prodrug concentrations than 250 μM to the MDCK cell cultures. Thus, these metabolic experiments could unfortunately not reveal the basis for the failure of the 5-bromouridine phosphoramidate prodrug as a potential antiviral agent in cell culture.




Fig. 1. Enzymatic experiment of **20a** with carboxypeptidase Y.

Table 3

Data collected from the enzymatic experiment with carboxypeptidase Y in Fig. 1.

Time (min)	Phosphoramidate 20a (%) δp 4.06, 3.83	Metabolite i (%) δp 4.93, 4.86	Metabolite ii (%) δp 6.66
0	100	0	0
7	45	36	19
14	21	37	42
21	10	24	66
28	8	7	75
56	6	3	91
60	0	0	100

3.5. Enzymatic studies

3.5.1. Carboxypeptidase Y assay

The putative mechanism of bioactivation of the ProTides proceeds in four steps starting with the cleavage of the ester moiety mediated by an esterase or carboxypeptidase type enzyme, followed by the spontaneous intracellular displacement of the aryloxy group which leads to the formation of an unstable five-membered cyclic mixed anhydride. The last step involves the cleavage of the P–N bond by an intracellular phosphoramidase-type enzyme with consequent release of the nucleoside 5'-monophosphate (Saboulard et al., 1999).

An enzymatic study using carboxypeptidase Y enzyme was carried out with the intent to study the first step of the activation pathway yielding the aminoacyl intermediate (Birkus et al., 2007, 2011). The experiment was performed using ^{31}P NMR, following the NMR spectra shift of the compounds during the process for 14 h (Fig. 1). Compound **20a** (5 mg) was dissolved in d_6 -acetone (0.15 mL) and Trizma buffer (0.30 mL) and a ^{31}P NMR was recorded. Then a solution of carboxypeptidase Y (0.1 mg) in Trizma buffer (0.15 mL) was added and ^{31}P NMR experiments were performed every 7 min for 14 h. The spectra show a relatively rapid hydrolysis of the starting material ($\delta p = 4.06, 3.83$ ppm) to the metabolite **i** ($\delta p = 4.93, 4.86$ ppm) and the metabolite **ii** ($\delta p = 6.66$ ppm). Metabolite **i** has been identified as the ProTide

without the ester in the amino acid moiety and bearing one negative charge, while metabolite **ii** as the intermediate bearing two negative charges, after the loss of the aromatic moiety. The two diastereoisomers appear to be processed with slightly different efficacy with one diastereoisomer being hydrolyzed faster than the other. Table 3 contains the data collected over the 14 h to show the different metabolites.

3.5.2. Cell lysate assay

An enzymatic study using cell lysate from HuH7 hepatocytes was carried out at 37 °C and the formation of the monophosphate species was followed by ^{31}P NMR. Compound **19a** was considered for this study.

From the experiment shown in Fig. 2, there was no evidence of formation of the aminoacyl derivative (**ii**) and this suggested a quick enzymatic hydrolysis of the intermediate, but an overall slow bioactivation of the ProTide to the 5'-monophosphate. The deconvoluted spectra clearly showed only two species (compound **19a** and its monophosphate nucleotide) after 14 h in a ratio of 1:2 (Fig. 3).

4. Conclusion

The inhibitory effect of several base- or sugar-modified UTP derivatives observed in our influenza polymerase assays provided a rationale to design innovative nucleoside analogues for selective inhibition of influenza virus. The phosphoramidate ProTide technology was applied to the modified uridines, with the aim of improving their intracellular bioavailability and activation, and achieving an interesting antiviral activity. The uridine ProTides showed efficient processing in the enzymatic carboxypeptidase Y assay, and the cell lysate experiments suggested that these ProTides release their monophosphate metabolite inside the cells, although they are not completely metabolized. After antiviral evaluation in influenza virus-infected cells, we identified two ProTides derived from 2'-fluoro-2'-deoxyuridine showing moderate antiviral activity, **23a** ($\text{EC}_{99} = 49 \mu\text{M}$) and **23b** ($\text{EC}_{99} \geq 81 \mu\text{M}$), while




Fig. 2. Enzymatic experiment with **19a** incubated with HuH7 cell lysate during 14 h at 37 °C.




Fig. 3. Deconvoluted ^{31}P NMR of the enzymatic experiment in Fig. 3.

the parent nucleoside analogue showed no activity in cell culture. In the viral polymerase assay, the corresponding triphosphate derivative had an inhibitory activity (IC_{50}) of 14 μM . Based on the kinetic results obtained with the cell lysate, we hypothesize that these uridine phosphate ProTides may be slowly processed to release the active monophosphate species. Another possible explanation for their weak antiviral activity could be the inefficient di- or triphosphorylation of the substituted uridine 5'-monophosphate after its release inside the cells, resulting in poor levels of the active 5'-triphosphate metabolite.

Acknowledgements

The authors Wim van Dam, Leentje Persoons and Ria Van Berwaer for excellent technical assistance and Dr. Laurence Tiley for providing the detailed enzyme purification procedure. This work was supported by Grants from the Katholieke Universiteit Leuven (to E.V.); the Fonds voor Wetenschappelijk Onderzoek Vlaanderen (FWO No. 9.0188.07) and the Geconcerteerde Onderzoeksacties (GOA/10/014).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.antiviral.2012.01.007](https://doi.org/10.1016/j.antiviral.2012.01.007).

References

- Asakura, J., Robins, M.J., 1990. Cerium (IV)-mediated halogenation at C-5 of uracil derivatives. *J. Org. Chem.* 55, 4928–4933.
- Birkus, G., Wang, R., Liu, X., Kutty, N., MacArthur, H., Cihlar, T., Gibbs, C., Swaminathan, S., Lee, W., McDermott, M., 2007. Cathepsin A is the major

- hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131. *Antimicrob. Agents Chemother.* 51, 543–550.
- Birkus, G., Kutty, N., Frey, C.R., Shribata, R., Chou, T., Wagner, C., McDermott, M., Cihlar, T., 2011. Role of Cathepsin A and lysosomes in the intracellular activation of novel antipapillomavirus agent GS-9191. *Antimicrob. Agents Chemother.* 55, 2166–2173.
- Cahard, D., McGuigan, C., Balzarini, J., 2004. Aryloxy Phosphoramidate Triesters as ProTides. *Mini-Rev. Med. Chem.* 4, 371–382.
- De Clercq, E., Field, H.J., 2008. Antiviral chemistry and chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses. *Antiviral Chem. Chemother.* 19, 75–105.
- Derudas, M., Carta, D., Brancale, A., Vanpouille, C., Lisco, A., Margolis, L., Balzarini, J., McGuigan, C., 2009. The application of phosphoramidate ProTide technology to acyclovir confers anti-HIV inhibition. *J. Med. Chem.* 52, 5520–5530.
- Deval, J., Powdrill, M.H., D'Abramo, C.M., Cellai, L., Götte, M., 2007. Pyrophosphorylolytic excision of nonobligate chain terminators by hepatitis C virus NS5B polymerase. *Antimicrob. Agents Chemother.* 51 (8), 2920–2928.
- Field, H.J., De Clercq, E., 2008. Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses. *Antiviral Chem. Chemother.* 19, 51–62.
- Hecker, S.J., Erion, M.D., 2008. Prodrugs of phosphates and phosphonates. *J. Med. Chem.* 51, 2328–2345.
- Hocek, M., Fojta, M., 2008. Cross-coupling reactions of nucleoside triphosphates followed by polymerase incorporation. Construction and applications of base-functionalized nucleic acids. *Org. Biomol. Chem.* 6 (13), 2233–2241.
- Jones, R.J., Bischofberger, N., 1995. Minireview: nucleotide prodrugs. *Antiviral Res.* 27, 1–17.
- Mehellou, Y., Balzarini, J., McGuigan, C., 2009. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells. *ChemMedChem* 4, 1779–1791.
- Meier, C., 1998. Pro-nucleotides – recent advances in the design of efficient tools for the delivery of biologically active nucleoside monophosphates. *Synlett*, 233–242.
- Nakayama, C., Saneyoshi, M., 1984. Utilizations of various uridine 5'-triphosphate analogues by DNA-dependent RNA polymerases I and II purified from liver nuclei of the cherry salmon (*Oncorhynchus masou*). *J. Biochem.* 96 (5), 1501–1509.
- Plotch, S.J., Bouloy, M., Ulmanen, I., Krug, R.M., 1981. A unique cap(m7G pppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. *Cell* 23 (3), 847–858.

- Resa-Infante, P., Jorba, N., Coloma, R., Ortin, J., 2011. The influenza virus RNA synthesis machine: advances in its structure and function. *RNA Biol.* 8 (2), 207–215.
- Rochovsky, O.M., 1976. RNA synthesis by ribonucleoprotein–polymerase complexes isolated from influenza virus. *Virology* 73 (2), 327–338.
- Saboulard, D., Naesens, L., Cahard, D., Salgado, A., Pathirana, R., Velazquez, S., McGuigan, C., De Clercq, E., Balzarini, J., 1999. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine (d4T) and Zidovudine (AZT). *Mol. Pharmacol.* 56, 693–704.
- Tisdale, M., Ellis, M., Klumpp, K., Court, S., Ford, M., 1995. Inhibition of influenza virus transcription by 2'-deoxy-2'-fluoroguanosine. *Antimicrob. Agents Chemother.* 39 (11), 2454–2458.
- Uchiyama, M., Aso, Y., Noyori, R., Hayakawa, Y.O., 1993. Selective phosphorylation of nucleoside without N-protection. *J. Org. Chem.* 58, 373–379.
- Van Rompay, A.R., Norda, A., Lindén, K., Johansson, M., Karlsson, A., 2001. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine–cytidine kinases. *Mol. Pharmacol.* 59 (5), 1181–1186.
- Vanderlinden, E., Göktas, F., Cesur, Z., Froeyen, M., Reed, M.L., Russell, C.J., Cesur, N., Naesens, L., 2010. Novel inhibitors of influenza virus fusion: structure–activity relationship and interaction with the viral hemagglutinin. *J. Virol.* 84 (9), 4277–4288.
- Vecchio, L., Solimando, L., Biggiogera, M., Fakan, S., 2008. Use of halogenated precursors for simultaneous DNA and RNA detection by means of immunoelectron and immunofluorescence microscopy. *J. Histochem. Cytochem.* 56 (1), 45–55.
- Vreede, F.T., Brownlee, G.G., 2007. Influenza virion-derived viral ribonucleoproteins synthesize both mRNA and cRNA in vitro. *J. Virol.* 81 (5), 2196–2204.
- Wagner, C.R., Iyer, V.V., McIntee, E.J., 2000. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. *Med. Res. Rev.* 20, 417–451.